Inhibikase Therapeutics Files Q1 2025 10-Q
Ticker: IKT · Form: 10-Q · Filed: May 14, 2025 · CIK: 1750149
| Field | Detail |
|---|---|
| Company | Inhibikase Therapeutics, INC. (IKT) |
| Form Type | 10-Q |
| Filed Date | May 14, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, biotech
TL;DR
IKT Q1 2025 10-Q filed. Shows stock, options, and past private placements.
AI Summary
Inhibikase Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial condition and business operations, including details on its common stock, employee stock options, and various financial instruments. The filing also references an ATM agreement and a private placement that occurred in October 2024 and May 2024.
Why It Matters
This filing provides investors with an update on Inhibikase Therapeutics' financial health and operational activities for the first quarter of 2025, crucial for understanding the company's current standing and future prospects.
Risk Assessment
Risk Level: medium — The company is in the biotechnology sector, which is inherently high-risk due to the nature of drug development and regulatory hurdles.
Key Numbers
- 2025-03-31 — Reporting Period End Date (Indicates the end of the financial quarter being reported.)
- 2025-01-01 — Reporting Period Start Date (Indicates the beginning of the financial quarter being reported.)
Key Players & Entities
- Inhibikase Therapeutics, Inc. (company) — Filer of the 10-Q
- 20250331 (date) — End of the reporting period
- October 2024 (date) — Date of ATM agreement and private placement
- May 2024 (date) — Date of private placement
FAQ
What is the total revenue for the quarter ending March 31, 2025?
The provided text does not contain specific revenue figures for the quarter ending March 31, 2025.
What was the net income or loss for the period?
The provided text does not specify the net income or loss for the period ending March 31, 2025.
What are the details of the ATM agreement mentioned?
The filing mentions an ATM agreement in conjunction with a private placement in October 2024 and May 2024, but specific details of the agreement are not provided in this excerpt.
What is the company's cash and cash equivalents balance as of March 31, 2025?
The provided text does not include the cash and cash equivalents balance as of March 31, 2025.
Are there any significant changes in selling, general, and administrative expenses compared to the previous year?
The filing indicates 'SellingGeneralAndAdministrativeExpensesMember' for the period January 1, 2025, to March 31, 2025, but does not provide comparative figures or details on changes.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 14, 2025 regarding Inhibikase Therapeutics, Inc. (IKT).